Aurobindo Pharma Q1 net rises 25% to ₹1,032 cr; approves merger of three arms
Aurobindo Pharma reported a 25.2% increase in net profit for the June quarter, driven by strong revenue growth in its U.S. and European formulation businesses. The company also announced the merger of three of its subsidiaries to streamline operations and reduce administrative overhead.
Why it matters
The merger and strong financial performance reflect ongoing consolidation and growth strategies within the global generic pharmaceutical market.
Generic drugmaker Aurobindo Pharma reported a 25.2% year-on-year (YoY) increase in consolidated net profit to ₹1,032 crore in the June quarter FY27.
The higher net profitability came on a 16.3% YoY increase in revenue from operations to ₹9,150 crore on the back of growth across businesses.
Formulations revenue surged 16.5% YoY to ₹8,101 crore, including a 8.1% YoY increase in the U.S. revenue to ₹3,770 crore ($399 million) and 25.6% in Europe revenue to ₹2,937 crore (€267 million). Total API revenue rose 14.6% YoY to ₹1,049 crore in the review quarter.
On the U.S. formulations revenue, the company, in a release, said the increase was primarily driven by volume gains and new launches, partially offset by no transient product sales; while in Europe, the formulations revenue was driven by robust performance across all key markets.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in